NCT03962543 2025-08-07ReNeuSpringWorks Therapeutics, Inc.Phase 2 Active not recruiting114 enrolled 25 charts 1 FDA
NCT02096471 2019-01-10MEK InhibitorUniversity of Alabama at BirminghamPhase 2 Completed19 enrolled 14 charts